ArticleIranian journal of pathology2026
EZH2 and MMP1 Overexpression in Colorectal Cancer: Correlation with Tumor Aggressiveness and Clinicopathologic Features.
Article in Iranian journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objective: One of the most lethal as well as prevalent malignancies across the globe is colorectal cancer (CRC). MMP1, a certain type of matrix metalloproteinase, as well as EZH2, a histone methyltransferase, are gaining attention for their part in metastasis and tumor progression. This research analyses the expression of immunohistochemistry EZH2 and MMP1 in relation to colorectal carcinoma, and how these two proteins correlate with other clinicopathological features. Methods: An analysis was done retrospectively on 38 cases of colorectal cancer, which were formalin-fixed and paraffin-embedded. MMP1 and EZH2 staining were assessed immunohistochemically and correlated with the tumor's stage, lymph nodes, clinical stage, and prognosis. Statistical analysis was conducted with SPSS version16.0 and a level of significance of p <0.05. Results: Markedly increased expression of EZH2 and MMP1 had notable correlation with advanced T stage (p =0.01 and0.03) along with metastasis to the regional lymph nodes (p =0.027) and clinical stages III or IV (p =0.04 for EZH2 and p =0.023 for MMP1). Although both markers demonstrated a trend for decreased disease-free survival (DFS), neither achieved statistical significance for DFS or overall survival (OS). Conclusion: EZH2 and MMP1 overexpression were associated with aggressive clinicopathologic features (higher T stage, nodal involvement, and advanced clinical stage). However, neither marker showed a statistically significant association with overall survival (OS) or disease-free survival (DFS) in this cohort. Larger, adequately powered studies are required to clarify any potential prognostic value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.